206 related articles for article (PubMed ID: 22923991)
1. Intracellular CXCR4⁺ cell targeting with T22-empowered protein-only nanoparticles.
Unzueta U; Céspedes MV; Ferrer-Miralles N; Casanova I; Cedano J; Corchero JL; Domingo-Espín J; Villaverde A; Mangues R; Vázquez E
Int J Nanomedicine; 2012; 7():4533-44. PubMed ID: 22923991
[TBL] [Abstract][Full Text] [Related]
2. Collaborative membrane activity and receptor-dependent tumor cell targeting for precise nanoparticle delivery in CXCR4
Sala R; Sánchez-García L; Serna N; Céspedes MV; Casanova I; Roldán M; Sánchez-Chardi A; Unzueta U; Vázquez E; Mangues R; Villaverde A
Acta Biomater; 2019 Nov; 99():426-432. PubMed ID: 31494293
[TBL] [Abstract][Full Text] [Related]
3. Recruiting potent membrane penetrability in tumor cell-targeted protein-only nanoparticles.
Serna N; Sánchez JM; Unzueta U; Sánchez-García L; Sánchez-Chardi A; Mangues R; Vázquez E; Villaverde A
Nanotechnology; 2019 Mar; 30(11):115101. PubMed ID: 30561375
[TBL] [Abstract][Full Text] [Related]
4. Engineering tumor cell targeting in nanoscale amyloidal materials.
Unzueta U; Seras-Franzoso J; Céspedes MV; Saccardo P; Cortés F; Rueda F; Garcia-Fruitós E; Ferrer-Miralles N; Mangues R; Vázquez E; Villaverde A
Nanotechnology; 2017 Jan; 28(1):015102. PubMed ID: 27893441
[TBL] [Abstract][Full Text] [Related]
5. CXCR4-targeted nanotoxins induce GSDME-dependent pyroptosis in head and neck squamous cell carcinoma.
Rioja-Blanco E; Arroyo-Solera I; Álamo P; Casanova I; Gallardo A; Unzueta U; Serna N; Sánchez-García L; Quer M; Villaverde A; Vázquez E; León X; Alba-Castellón L; Mangues R
J Exp Clin Cancer Res; 2022 Feb; 41(1):49. PubMed ID: 35120582
[TBL] [Abstract][Full Text] [Related]
6. Selective delivery of T22-PE24-H6 to CXCR4
Falgàs A; Pallarès V; Serna N; Sánchez-García L; Sierra J; Gallardo A; Alba-Castellón L; Álamo P; Unzueta U; Villaverde A; Vázquez E; Mangues R; Casanova I
Theranostics; 2020; 10(12):5169-5180. PubMed ID: 32373205
[No Abstract] [Full Text] [Related]
7. Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of tachyplesin analogs to CXCR4.
Xu Y; Tamamura H; Arakaki R; Nakashima H; Zhang X; Fujii N; Uchiyama T; Hattori T
AIDS Res Hum Retroviruses; 1999 Mar; 15(5):419-27. PubMed ID: 10195751
[TBL] [Abstract][Full Text] [Related]
8. Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4
Falgàs A; Pallarès V; Unzueta U; Núñez Y; Sierra J; Gallardo A; Alba-Castellón L; Mangues MA; Álamo P; Villaverde A; Vázquez E; Mangues R; Casanova I
Int J Nanomedicine; 2021; 16():1869-1888. PubMed ID: 33716502
[TBL] [Abstract][Full Text] [Related]
9. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection.
Murakami T; Nakajima T; Koyanagi Y; Tachibana K; Fujii N; Tamamura H; Yoshida N; Waki M; Matsumoto A; Yoshie O; Kishimoto T; Yamamoto N; Nagasawa T
J Exp Med; 1997 Oct; 186(8):1389-93. PubMed ID: 9334379
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection.
Murakami T; Zhang TY; Koyanagi Y; Tanaka Y; Kim J; Suzuki Y; Minoguchi S; Tamamura H; Waki M; Matsumoto A; Fujii N; Shida H; Hoxie JA; Peiper SC; Yamamoto N
J Virol; 1999 Sep; 73(9):7489-96. PubMed ID: 10438838
[TBL] [Abstract][Full Text] [Related]
11. The biodistribution of self-assembling protein nanoparticles shows they are promising vaccine platforms.
Yang Y; Neef T; Mittelholzer C; Garcia Garayoa E; Bläuenstein P; Schibli R; Aebi U; Burkhard P
J Nanobiotechnology; 2013 Nov; 11():36. PubMed ID: 24219600
[TBL] [Abstract][Full Text] [Related]
12. Pharmacophore identification of a chemokine receptor (CXCR4) antagonist, T22 ([Tyr(5,12),Lys7]-polyphemusin II), which specifically blocks T cell-line-tropic HIV-1 infection.
Tamamura H; Imai M; Ishihara T; Masuda M; Funakoshi H; Oyake H; Murakami T; Arakaki R; Nakashima H; Otaka A; Ibuka T; Waki M; Matsumoto A; Yamamoto N; Fujii N
Bioorg Med Chem; 1998 Jul; 6(7):1033-41. PubMed ID: 9730240
[TBL] [Abstract][Full Text] [Related]
13. Selective CXCR4
Díaz R; Pallarès V; Cano-Garrido O; Serna N; Sánchez-García L; Falgàs A; Pesarrodona M; Unzueta U; Sánchez-Chardi A; Sánchez JM; Casanova I; Vázquez E; Mangues R; Villaverde A
Small; 2018 Jun; 14(26):e1800665. PubMed ID: 29845742
[TBL] [Abstract][Full Text] [Related]
14. Cancer-specific uptake of a liganded protein nanocarrier targeting aggressive CXCR4
Céspedes MV; Unzueta U; Álamo P; Gallardo A; Sala R; Casanova I; Pavón MA; Mangues MA; Trías M; López-Pousa A; Villaverde A; Vázquez E; Mangues R
Nanomedicine; 2016 Oct; 12(7):1987-1996. PubMed ID: 27085904
[TBL] [Abstract][Full Text] [Related]
15. A diphtheria toxin-based nanoparticle achieves specific cytotoxic effect on CXCR4
Falgàs A; Garcia-León A; Núñez Y; Serna N; Sánchez-Garcia L; Unzueta U; Voltà-Durán E; Aragó M; Álamo P; Alba-Castellón L; Sierra J; Gallardo A; Villaverde A; Vázquez E; Mangues R; Casanova I
Biomed Pharmacother; 2022 Jun; 150():112940. PubMed ID: 35421785
[TBL] [Abstract][Full Text] [Related]
16. An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination.
Pallarès V; Unzueta U; Falgàs A; Sánchez-García L; Serna N; Gallardo A; Morris GA; Alba-Castellón L; Álamo P; Sierra J; Villaverde A; Vázquez E; Casanova I; Mangues R
J Hematol Oncol; 2020 Apr; 13(1):36. PubMed ID: 32295630
[TBL] [Abstract][Full Text] [Related]
17. Design and evaluation of a CXCR4 targeting peptide 4DV3 as an HIV entry inhibitor and a ligand for targeted drug delivery.
Heon Lee I; Palombo MS; Zhang X; Szekely Z; Sinko PJ
Eur J Pharm Biopharm; 2019 May; 138():11-22. PubMed ID: 29894816
[TBL] [Abstract][Full Text] [Related]
18. Antibacterial Activity of T22, a Specific Peptidic Ligand of the Tumoral Marker CXCR4.
Serna N; Carratalá JV; Conchillo-Solé O; Martínez-Torró C; Unzueta U; Mangues R; Ferrer-Miralles N; Daura X; Vázquez E; Villaverde A
Pharmaceutics; 2021 Nov; 13(11):. PubMed ID: 34834337
[TBL] [Abstract][Full Text] [Related]
19. Antineoplastic effect of a diphtheria toxin-based nanoparticle targeting acute myeloid leukemia cells overexpressing CXCR4.
Pallarès V; Núñez Y; Sánchez-García L; Falgàs A; Serna N; Unzueta U; Gallardo A; Alba-Castellón L; Álamo P; Sierra J; Villaverde A; Vázquez E; Casanova I; Mangues R
J Control Release; 2021 Jul; 335():117-129. PubMed ID: 34004204
[TBL] [Abstract][Full Text] [Related]
20. Paradoxical downregulation of CXC chemokine receptor 4 induced by polyphemusin II-derived antagonists.
Masuda R; Oishi S; Tanahara N; Ohno H; Hirasawa A; Tsujimoto G; Yano Y; Matsuzaki K; Navenot JM; Peiper SC; Fujii N
Bioconjug Chem; 2012 Jun; 23(6):1259-65. PubMed ID: 22486464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
